Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
1
institution
Market cap
$294.8M
13M shares
52-week range
$8.22 β $22.88
88% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
www.anika.comNo one on the platform currently holds ANIK.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 502,217 | $7.3M |
No one on the platform has traded ANIK yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ANIK 40 stock in 2027 , new CEO fantastic
View on StockTwits βThese 2 Biotech Stocks Hit New 52-Week Highs Today β And CORT Clocked Its Best Day In Nearly 16 Months $CORT $ANIK $XBI https://stocktwits.com/news/equity/markets/cort-stock-52-week-high-q2-results-anika-therapeutics-outlook/cZN5JErRJ2c
View on StockTwits βhttps://www.marketbeat.com/earnings/reports/2026-7-29-anika-therapeutics-inc-stock/ $ANIK Anika Therapeutics Earnings Transcript
View on StockTwits βYields firming up post-earnings setups... $ANIK jumped on record margins and 16% YoY revenue growth, but the market is trading the turnaround against pipeline reality. That keeps quality execution in focus versus broader medtech names
View on StockTwits β$ANIK detailed its second-quarter 2026 financial results in a press release.
View on StockTwits β$ANIK Q2 '26 Earnings Results & Recap β’ Reported GAAP EPS of $0.25 up 189.29% YoY β’ Reported revenue of $32.61M up 15.56% YoY β’ Anika Therapeutics, Inc. is raising its full-year 2026 revenue growth guidance to 5% to 10% and its adjusted EBITDA margin outlook to 13% to 17% for the fiscal year.
View on StockTwits β@NVDAMillionaire thanks great info , ive been trading this , but im locked in now for the long haul , $HONA $APLD $ANIK my 2026 second half trades ! what do you like ?
View on StockTwits β@Truenorthtrades1 $Apld , $ANIK , $HONA my 3 picks for 2nd half of 2026
View on StockTwits β$FEIM $ANIK $QMCO $ONEI Good morning, investors. AI infrastructure spending continues expanding beyond software into power, data centers, and physical infrastructure, creating new opportunities across technology, utilities, and energy services. On the watchlist, $FEIM continues standing out after a strong year, while $ANIK is benefiting from improving operational momentum. $QMCO remains a higher risk turnaround story after a difficult year. Among gainers, $LUCD climbed 15% on continued interest in its cancer detection platform. On the downside, $MICW fell 16% as investors questioned its expansion outlook. Read the full Analytica Alpha π https://analyticainvestor.beehiiv.com/p/market-pulse-lucid-15
View on StockTwits β$ANIK wow these spreads are crazy in this stock ! Grinding higher
View on StockTwits βbullish engulfing week out of the tightness Jon $ANIK as itβs all coming together in HRMY as MAMA said it gets LGNDary ENTA πππ§ β°βΎοΈ
View on StockTwits β$ANIK Share Price: $14.40 Contract Selected: Dec 18, 2026 $15 Calls Buy Zone: $1.19 β $1.47 Target Zone: $1.98 β $2.42 Potential Upside: 57% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits β$ANIK Implied Volatility Drops to 1.38 for Anika Therapeutics https://www.macroaxis.com/stock-options/ANIK/Anika-Therapeutics?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $122M | +10.1% | $0.53 | $0.53β$0.53 | 39.9Γ | 1 |
| 2027 | $129M | +5.2% | $0.73 | $0.73β$0.74 | 28.8Γ | 1 |
| 2028 | $138M | +7.1% | $1.15 | $1.14β$1.16 | 18.4Γ | 1 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $0.03 | $0.42 | +1300.0% |
| 2026-04-29 | $-0.07 | $0.27 | +485.7% |
| 2026-02-26 | $-0.13 | $0.31 | +348.0% |
| 2025-11-05 | $0.02 | $0.04 | +100.0% |
| 2025-07-30 | $-0.13 | $-0.13 | +0.0% |
| 2025-05-09 | $0.09 | $-0.06 | -166.7% |
| 2025-03-12 | $-0.01 | $-0.03 | -200.0% |
| 2024-10-31 | $0.30 | $-0.25 | -183.3% |
| $868M |
| β |
| LNSRLENSAR Inc | $8.27 | +31.48% | $102M | β |
| LUCDLucid Diagnostics Inc. | $0.96 | -1.98% | $184M | β |
Source: Financial Modeling Prep Β· peers by sector/industry